mbiomics GmbH

mbiomics GmbH is a biotechnology company based in Munich, Germany, founded in 2020. The company focuses on designing and developing microbiome-based therapeutics aimed at treating severe and chronic diseases. Co-founders Laura Figulla, Markus Rinecker, and Johannes Wöhrstein lead a team dedicated to advancing the understanding of the gut microbiome's interactions with the host.

The company has created a proprietary high-resolution profiling platform that generates precision data on microbiota modulation. This technology allows mbiomics to design complex microbial consortia, offering an end-to-end solution that includes over 100 different gut bacteria. Their product line includes live bacterial therapeutics and live biotherapeutic products targeting various health conditions, such as immune-oncology and inflammatory bowel diseases. With a focus on innovative therapeutic strategies, mbiomics aims to establish itself as a significant player in the field of synthetic microbial consortia.